Description: TAS-102 (a mixture of Trifluridine and tipiracil hydrochloride in a 1:0.5 molar ratio) is a combination drug under investigation for treating metastatic colorectal cancer. It is an orally bioavailable combination drug composed of trifluridine (TFT), an antineoplastic thymidine-based nucleoside analog, and Tipiracil hydrochloride (TTP), a potent thymidine phosphorylase inhibitor, in a molar ratio of 1 : 0.5.

References: [1]. Uboha N, et al. TAS-102: a novel antimetabolite for the 21st century. Future Oncol. 2016 Jan;12(2):153-63.; [2]. Nukatsuka M, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015 Mar;35(3):1437-45.

Related CAS #: 733030-01-8 (183204-72-0 (Tipiracil HCl) 70-00-8 (Trifluridine)

纯度：≥98%

CAS：733030-01-8